Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EDAP TMS ( (EDAP) ) has provided an announcement.
On January 12, 2026, EDAP TMS reported select preliminary unaudited results indicating record high-intensity focused ultrasound (HIFU) revenue for both the fourth quarter and full year 2025, driven by strong global demand for its Focal One systems and rising procedure volumes, particularly in the United States. Fourth-quarter 2025 worldwide HIFU revenue is expected between $12.9 million and $13.3 million, and annual 2025 HIFU revenue between $36.7 million and $37.2 million, while non-core distribution and ESWL operations are expected to contribute $7.9 million to $8.3 million for the quarter and $32.7 million to $33.1 million for the year. Management highlighted a record 15 Focal One placements in the quarter, a 69% year-on-year increase in annual system placements, and around 28% year-on-year growth in U.S. procedures in the fourth quarter, underscoring a growing recurring revenue base and signaling that HIFU now represents more than half of expected annual revenue. EDAP also issued initial 2026 guidance, projecting $50 million to $54 million in core HIFU revenue and $22 million to $26 million in non-core revenue, while cautioning that the figures are preliminary and subject to adjustment pending completion of year-end reporting and external review, with final 2025 results slated for release in March 2026.
The most recent analyst rating on (EDAP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.
Spark’s Take on EDAP Stock
According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow). Technicals are supportive with a clear uptrend, but overbought signals add near-term risk. Earnings call trends in the core HIFU business and maintained guidance are positives, while negative P/E and no dividend reduce valuation support.
To see Spark’s full report on EDAP stock, click here.
More about EDAP TMS
EDAP TMS SA, listed on Nasdaq, is a recognized leader in robotic energy-based therapies that develops, manufactures, promotes and distributes minimally invasive medical devices using ultrasound technology. Combining advanced imaging, robotics and non-invasive energy delivery, the company’s flagship Focal One® system is positioned as a leading urologist-controlled prostate focal therapy platform in Europe and the U.S., with potential applications beyond prostate cancer, targeting hospitals and urology centers worldwide.
Average Trading Volume: 65,649
Technical Sentiment Signal: Hold
Current Market Cap: $137.6M
For an in-depth examination of EDAP stock, go to TipRanks’ Overview page.